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Effect of renal artery revascularization on left
ventricular hypertrophy, diastolic function, blood
pressure, and the one-year outcome
Daniel Rzeznik, MD, Tadeusz Przewlocki, MD, PhD, Anna Kablak-Ziembicka, MD, PhD,
Artur Kozanecki, MD, Agnieszka Roslawiecka, MD, Jacek Lach, MSc, Wieslawa Tracz, MD, PhD, and
Piotr Podolec, MD, PhD, Krakow, Poland
Objective: The study aimed to determine the potential interrelations between left ventricle mass (LVM), LV diastolic
function, systolic blood pressure (SBP) and diastolic blood pressure (DBP) and cardiovascular events in patients
undergoing renal artery stenosis (RAS).
Methods: Prior to RAS, 3 and 12 months afterward, the change in LVM, left ventricular mass index (LVMI), diastolic
function (E/A ratio, E= wave velocity, isovolumetric relaxation time [IVRT], E/E= ratio) on echocardiography and
change in SBP and DBP on 24-hour monitoring were assessed in 84 patients, aged 63.7 10 years, who underwent RAS
for renal artery stenosis > 60%.
Results: During 12 months, 12 (14.3%) cardiovascular (CV) events (five deaths) occurred. At 1 year, the mean LVM
decreased from 179  49 g to 141  31 g (P < .001), LVMI in men decreased from 100  20 g/m2 to 79  18 g/m2
(P < .001), and the LVMI in women decreased from 96  18 g/m2 to 80  17 g/m2 (P < .001). No improvement in
diastolic function parameters was seen. The mean SBP and DBP decreased from 133.5  16.9 mm Hg to 127.9  13.2
mmHg (P .007) and from 75.4 10.2 mmHg to 73.1 8.8 mmHg (P .035), respectively. Onmultivariate logistic
regression analysis, coronary artery disease (CAD) severity (relative risk [RR], 1.27; P  .023), smoking (RR, 1.29;
P  .016), and baseline LVM (RR, 1.21; P  .07) were found as independent CV event risk factors. The independent
factors associated with SBP and DBP improvement were grade of renal stenosis (RR, 1.28; P  .006), bilateral RAS
procedure (RR, 1.17; P .07), and baseline DBP value (RR, 1.74; P< .001). LVM reduction was associated with higher
baseline ejection fraction (RR, 1.53; P< .001) and baseline LVM (RR, 1.7; P< 0.001). SBP andDBP value changes were
independent of LVM change (r  0.031; P  .796 and r  0.098; P  .413, respectively).
Conclusions: RAS induced LVM and LVMI reduction, which is independent of the change in blood pressure. Baseline
LVM is associated with higher CV event risk following RAS. (J Vasc Surg 2011;53:692-7.)
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pRenal artery stenosis (RAS) occurs in 5% of subjects
with hypertension, and it is more frequently encountered in
patients with atherosclerotic lesions in coronary, lower
limb, or supra-aortic arteries.1-5
A significant RAS may lead to activation of the renin-
angiotensin-aldosterone system andmay result in hyperten-
sion and left ventricular hypertrophy.6 Several neurohor-
monal mechanisms of this action are postulated.7,8 RAS is
associated with progressive renal dysfunction and the in-
creased cardiovascular events rate.9 Furthermore, left ven-
tricular (LV) hypertrophy has a negative impact on survival
and it is an independent risk factor of cardiovascular events,
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692ncluding cardiovascular death and myocardial infarc-
ion.7,10
There are many conflicting data on the impact of RAS
n blood pressure control.11,12 In the observational clinical
eries, blood pressure was reduced in about two-thirds of
atients who underwent the RAS procedure; however, the
esults of randomized trials are negative or indicate only a
orderline/mild impact of RAS procedure on blood pres-
ure.13 Also, there are little data on whether RAS may lead
o left ventricular hypertrophy reduction.14,15 The other
nteresting issue is whether reduced diastolic function,
ommonly present in hypertensive patients, may be influ-
nced by the RAS procedure and whether this action may
e associated with blood pressure values.16
The present study aimed to determine whether stenting
f RAS may lead to regression of LV hypertrophy and
mprovement in the LV diastolic function. Also, the study
imed to assess the interrelation between potential changes
n LV mass and diastolic function and blood pressure. We
ought for predictors of cardiovascular (CV) events at 1
ear following RAS procedure.
ETHODS
This prospective study comprised 84 (42 male, 50%)
atients with hypertension, aged 63.7  10 years (range,
0-81 years), referred to RAS for a mean renal artery
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Volume 53, Number 3 Rzeznik et al 693stenosis exceeding 60% lumen reduction, in the period
from January 2005 to May 2009. Bilateral renal stenosis
had 27 (32.1%) patients and renal stenosis of the single
functioning kidney had seven (9.2%).
The study protocol was reviewed and approved by the
local ethical committee and all patients signed informed
consent.
Arterial hypertension defined as values of systolic blood
pressure (SBP)140 mmHg and/or diastolic blood pres-
sure (DBP) 90 mm Hg was diagnosed in all subjects.
Hypertension crisis was observed in 33 (39.2%) and pul-
monary flash edema in five (5.9%) patients.
The impact of RAS on arterial hypertension was as-
sessed with 24-hour ambulatory blood pressure monitor-
ing prior to RAS procedure, then at 3 and 12 months
afterward. The mean SBP and DBP, as well as SBP and
DBP loads, were assessed and analyzed.
In all patients, serum creatinine level was determined,
and estimated glomerular filtration rate (eGFR) was calcu-
lated according to the Cockroft-Gault formula. Renal fail-
ure, defined as eGFR 60 mL/min, was found in 48
(57.1%) patients.
Coronary artery disease (confirmed on coronary an-
giography) was present in 53 (63.1%) patients. A detailed
characteristic of study participants is presented in Table I.
An echocardiographic study was performed in all pa-
tients at baseline and at 3 and 12 months after RAS.
Echocardiographic measurements
Patients were examined at bedside in a supine position
with the Toshiba Aplio SSA-770A (NasuWorks, Ottawara,
Japan). All echocardiographic recordings were acquired
with a multifrequency Doppler transducer placed at the
cardiac apical window during normal respiration according
to the guidelines of the American Society of Echocardiog-
raphy.17,18 Left ventricular ejection fraction was deter-
mined by two-dimensional echocardiography.
Left ventricle mass and mass index. The following
M-mode measurements were obtained according to the
American Society of Echocardiographers’ convention: in-
Table I. Baseline characteristic of study participants
Age, years  SD 63.7  10
Male, n (%) 42 (50)
Hypertension, n (%) 84 (100)
Hypertension crisis, n (%) 33 (39.2)
Diabetes, n (%) 18 (23.4)
Hyperlipidemia, n (%) 82 (97.6)
Current smoking, n (%) 35 (41.6)
Pulmonary flash edema, n (%) 5 (5.9)
Coronary artery disease*, n (%) 53 (63.1)
eGFR, mL/min  SD 58  26.2
eGFR  60 mL/min, n (%) 48 (57.1)
Systolic BP, mm Hg  SD 134.5  18.7
Systolic BP load, %  SD 46.1  30.2
Diastolic BP, mm Hg  SD 75.1  10.6
Diastolic BP load, %  SD 27.3  23.0
BP, Blood pressure; eGFR, estimated glomerular filtration rate.traventricular septum thickness at the end diastole (IVSd), sosterior wall thickness at the end diastole (PWd), and left
entricular internal dimension at end diastole (LVIDd).17
LVM was calculated with the anatomically validated
ormula of Devereux19:
0,8 1,04 * [(LVIDd IVSd PWd) 3(LVIDd)3]
 0,6
he LVMI was obtained by normalizing the left ventricular
ass over the body surface (BSA).
LVMI [g ⁄ m2] LVM ⁄ BSA
esults of LVMI were analyzed for females and males
eparately.11
Left ventricle diastolic function assessment. Pulsed
oppler interrogation of mitral inflow was performed with
he sample volume between the tips of the mitral leaflets in
he apical four-chamber view with the use of 1.5-mm
ample volume aligned with color inflow. Mitral inflow
arameters included early (E) and late (A) atrial mitral
nflow velocities, early-to-late mitral inflow velocity ratio
E/A). IVRTwasmeasured with continuous waveDoppler
chocardiography from aortic valve closure click to the
nset of mitral inflow, with the cursor positioned midway
etween left ventricular outflow and mitral inflow. For
issue Doppler recordings, a 1.5-mm sample volume was
laced at the medial mitral annulus since it is more repro-
ucible. Velocity of the early diastolic myocardial motion
E=) wave was measured. The E/E= ratio was calculated.
All Doppler signals were recorded for 5 to 10 cardiac
ycles at a sweep speed of 100 mm/sec and stored on a
HS videotape for later playback and analysis. The average
f three end-expiratory cycles was used.
nvasive procedure
Medical treatment prior to and after RAS was recorded
nd analyzed.
Eligibility criteria were determined on the basis of
ublished guidelines for percutaneous revascularization of
he RAS.1 In brief, the decision to perform RAS was
eached based on the clinical assessment, evaluated renal
unction or drug-resistant or malignant hypertension, and
he grade of RAS exceeding 60% lumen reduction. The
ain indication for the RAS procedure was ill-controlled
rterial hypertension in 41 (48.8%) patients (despite admin-
stration of at least three antihypertensive medications,
ncluding at least one diuretic), pulmonary flash edema in
ve (5.9%) patients, and progressive renal failure in 47
55.9%) patients. Thus, in nine patients, more than one
ndication for RAS was met.
The grade of renal stenosis was determined angio-
raphically immediately prior to RAS procedure with quan-
itative angiography (COROSCOP, Siemens, and Quant-
or QCA V4.0 software for quantitative analysis, Erlangen,
ermany).
Balloon angioplasty alone was done in five (5.9%) pa-
ients with fibromuscular dysplasia, while stents were im-
lanted in all the remaining patients with atherosclerotic
tenosis. Direct stenting was performed in 65 (82.3%) and
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March 2011694 Rzeznik et alpredilation in 14 (17.7%) patients. The bilateral RAS pro-
cedure was performed in 20 (23.8%) patients.
The procedure was technically successful in all patients.
Major periprocedural complications occurred in three
(3.5%) patients, including renal hematoma in one, acute
lower limb ischemia requiring urgent surgery in one, and
bleeding requiring blood transfusion in one. Access hema-
toma was observed in five (5.9%) patients.
Patient follow-up and cardiovascular events at 1 year
The incidences of CV death, myocardial infarction
(MI), ischemic stroke (IS), or a new revascularization for
lesion progression were recorded. CV death was defined as
a fatal IS, fatal MI, heart failure, or other cardiovascular
death (ie, any sudden or unexpected death [while sleeping]
unless proven as noncardiovascular on autopsy) were re-
corded.
IS diagnosis had to be sourced from a neurologist or
hospital files to ensure a reliable diagnosis. Lesion progres-
sion was defined as an increase in lesion stenosis to 70%
requiring revascularization, in the location with prior ste-
nosis 50%.
Composite end point was defined as CV death, fatal
and nonfatal MI and/or IS, and symptomatic lesion pro-
gression.
The improvement in SBP and DBP was defined as
reduction in the mean blood pressure values of 10 mm
Hg and5mmHg on 24-hour ambulatory blood pressure
monitoring. The deterioration of SBP and DBP was de-
fined as an increase in the respective values exceeding 10
mm Hg and 5 mm Hg. No significant change in blood
pressure values was assumed if SBP and DBP values were
within 10 mm Hg and 5 mm Hg baseline values, respec-
tively. Antihypertensive drug regimen reduction was also
considered as blood pressure improvement.
The significant reduction in LVM was defined as a
decrease in LVM by at least 15 g.
Statistical analysis
Continuous variables were presented as mean  one
standard deviation, and categorical variables as numbers
and percentages. Differences between analyzed parameters
were tested with Student t test and Mann-Whitney U-test,
or exact Chi-square and Fisher test where appropriate.
Spearman or Pearson correlation coefficient was used to
evaluate a relationship between change in SBP and in DBP
values and LV mass parameters and diastolic function.
Clinical risk factors, baseline blood pressure parame-
ters, renal function (eGFR), echocardiographic parameters,
CAD severity, unilateral vs bilateral renal stenosis and RAS
procedure, and the grade of renal stenosis were analyzed
with a univariate analysis model. Potential factors that may
be associated with the CV events rate, improvement in
blood pressure, LVM reduction, and diastolic function
were identified first with the univariate analysis, then fol-
lowed by multivariate logistic regression analysis, including
variables for which P value .1 was achieved from univar- 1ate analysis. The relative risk (RR) and confidence intervals
CI) were calculated for these factors.
Statistica 5.5 software (StatSoft, Tulsa, Okla) was used
or statistical analyses. Values were considered significant if
he P level was .05.
ESULTS
During 12-month follow-up, CV events occurred in 12
14.3%) patients, including CV death in five (5.9%) patients
three due to heart failure, one from MI, one due to IS),
onfatal MI in three, nonfatal IS in one, and symptomatic
esion progression requiring revascularization in three pa-
ients.
Patients who suffered from a CV event were more often
mokers (75% vs 36.1%; P  .011), more often had CAD
91.7% vs 58.3%; P  .027), and more advanced CAD
1.92 1.0 vs 1.0 1.0 coronary vessel stenosis; P .01),
ower baseline LV ejection fraction (54  14% vs 59.9 
0.5%; P .09), higher LVM (214 68 g vs 175 42 g;
 .008), and a history of hypertension crisis (66.7% vs
4.7%; P  .036). There were no significant differences
ith regard to grade of renal artery stenosis, the other
linical factors, and diastolic function parameters. Multivar-
ate logistic regression analysis revealed that only CAD
everity (RR, 1.27; CI, 1.04-1.56; P  .023), smoking
RR, 1.29; CI, 1.05-1.57; P  .016) and baseline LVM
RR, 1.21; CI, 0.99-1.49; P  .07) were identified as an
ndependent risk factors of a CV event (Table II).
The mean number of antihypertensive medications was
.2  1.0 before RAS, and this number was reduced to
.8  1.2 afterward (P  .009). In five (6.3%) patients,
rterial hypertension was cured, and in a further 20 (25.3%)
atients, at least one antihypertensive medication was dis-
ontinued. In six (7.6%) patients, antihypertensive regi-
ens had to be increased. Angiotensin-converting enzyme
ACE) and angiotensin-receptor blocker (ARB) inhibitors
ere taken by 50 (63.3%) subjects prior to RAS, and by 52
65.8%) at the 12-month follow-up period (P .752). The
ean SBP decreased from 133.5 16.9 mmHg to 127.9
able II. Independent predictors of CV event, LVM
eduction, and blood pressure improvement
ndependent predictors RR 95% CI P value
V event risk factors:
CAD severity 1.27 1.04-1.56 .023
Smoking 1.29 1.05-1.57 .016
Baseline LVM 1.21 0.99-1.49 .07
VM reduction:
Baseline LVM 1.70 1.4-2.06 .001
Baseline ejection fraction 1.53 1.26-1.85 .001
lood pressure improvement:
Grade of renal artery stenosis 1.28 1.08-1.51 .006
Bilateral RAS procedure 1.17 0.99-1.39 .070
Baseline DBP value 1.74 1.47-2.06 .001
AD, Coronary artery disease; CV, cardiovascular; DBP, diastolic blood
ressure; RAS, renal artery stenting.3.2 mm Hg (P  .007) and DBP from 75.4  10.2 mm
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Volume 53, Number 3 Rzeznik et al 695Hg to 73.1 8.8 mmHg (P .035; Table III). Also, SBP
and DBP loads were significantly reduced during 12-
month follow up.
Reduction in the mean SBP10 mmHg and DBP5
mm Hg was seen in 30 (37.9%) patients and deterioration
in 11 (13.9%), while no significant change was observed in
the remaining patients. Patients in whom blood pressure
improvement was observed were younger (60.7  12.1 vs
65.2  8.7 years; P  .058), had a higher grade of renal
artery stenosis (75.3 14.6% vs 64.6 10.6%; P .001),
more often had bilateral renal stenosis (47% vs 27%; P 
.068), and more often underwent a bilateral RAS proce-
dure (40% vs 16%; P  .019) as compared with those in
whom blood pressure (BP) values did not change or in-
creased after the RAS procedure. They had also higher
baseline values of SBP (148.2  15.8 mm Hg vs 125.7 
14.6 mmHg; P .001), DBP (83.8 8.9 mmHg vs 69.8
 7.9 mmHg; P .001), SBP load (64 21.9% vs 32.5
25.7%; P .001), and DBP load (46.8 24.8% vs 17.4
15.4%; P  .001).
The independent factors of blood pressure improve-
ment were: grade of renal artery stenosis (RR, 1.28; CI,
1.08-1.51; P  .006); bilateral RAS procedure (RR, 1.17;
CI, 0.99-1.39; P  .07); and baseline DBP value (RR,
1.74; CI, 1.47-2.06; P  .001; Table II).
The mean LVM decreased from baseline 179 49 g to
161  40 g at 3 months and to 141  31 g at 12 months
(P .001). In men, LVMI decreased from baseline 100
20 g/m2 to 90  23 g/m2 and to 79  18 g/m2 (P 
.001), while in women from 96  17 g/m2 to 90  18
g/m2 and to 80  17 g/m2 (P  .001) at 3 and 12
months, respectively (Table III). LVM reduction of at least
Table III. Echocardiographic and blood pressure paramet
patients who completed one-year observation (n  79)
Baseline At
EF, % 59  11.2
LVM, g  SD 179  49 1
LVMI in women, g/m2  SD 95  19
LVMI in men, g/m2  SD 105  25
IVSs, mm  SD 17  3.0 15
IVSd, mm  SD 12  2.6 10
E, cm/s  SD 85  26
E/A, 1  SD 1.02  0.38 1.
IVRT, ms  SD 115  26 1
E=, cm/s  SD 5.59  1.53 5.
E/E=, 1  SD 16.1  6.32 15
eGFR, mL/min  SD 58  26.2 68
eGFR  60 mL/min, n (%) 48 (57.1) 3
Systolic BP, mm Hg  SD 134.5  18.7 131
Systolic BP load, %  SD 46.1  30.2 41
Diastolic BP, mm Hg  SD 75.1  10.6 74
Diastolic BP load, %  SD 27.3  23.0 23
A=, Late diastolic velocity of mitral annulus, BP, blood pressure; E, early mit
mitral inflow velocity; E/E=, early-to-late mitral inflow velocity; eGFR, estima
pulsed-wave Doppler tissue imaging; IVSd, intraventricular septum thickne
LVM, left ventricle mass; LVMI, left ventricle mass index.15 g was observed in 55 (69.6%) patients, LVM increased L15 g in four (5.1%) patients, and LVM remained within
5 g in 20 (25.3%) patients.
Patients with LVM reduction had higher baseline ejec-
ion fraction (62%  10.3% vs 55%  10%; P  .016),
igher baseline LVM (188  43 g vs 153  29.5; P 
001), higher IVSd (12.6 2.5mm vs 10.4 2.1mm; P
001), and intraventricular septum thickness at the end
ystole (IVSs; 17.7  2.9 mm vs 14.5  2.2 mm; P 
001). In women and men, LVM reduction was greater
hen baseline LVMI was higher (women: 100  18.9
/g2 vs 85 13.4 m/g2; P .001; men: 106 21 m/g2
s 90  18.5 m/g2, P  .05). The independent factors
ssociated with LVM reduction were higher baseline ejec-
ion fraction (RR, 1.53; CI, 1.26-1.85; P .001) and high
aseline LVM (RR, 1.7; CI, 1.4-2.06; P .001; Table II).
No improvement in diastolic function parameters was
een (Table III). E/A ratio changed insignificantly from
.02  0.38 to 1.01  0.44 at 3 months and to 0.97 
.33 at 12months (P .341). E=wave increased from 5.59
1.6 cm/s to 5.97 2.2 cm/s and to 5.89 1.6 cm/s at
and 12 months, respectively (P  .093). IVRT changed
rom 114 26 ms to 111 21 ms and to 115 23 ms, at
and 12 months, respectively (P  .718; Table III).
inally, E/E= ratio decreased insignificantly from 16.4 
.2 to 16  7.7 at 3 months and to 15.1  8.0 at 12
onths (P  0.31; Table III).
There was a positive correlation between SBP and DBP
hange and E/A ratio at baseline (r  0.291; P  .017
nd r  0.379; P  .002, respectively). The SBP and
BP change between baseline and at 12-month follow-up
as independent of the degree of LVM reduction (r 
.031; P .796 and r 0.098; P .413, respectively) and
t baseline, at 3- and 12-month follow-up for those
nths At 12 months P value baseline vs 12 months
10 59  10.5 .354
39 143  32 .001
18 80  17 .001
21 79  18 .001
2.8 14.2  2.3 .001
2.1 10.1  1.8 .001
20 80  20 .893
0.4 0.97  0.33 .341
21 114  23 .718
2.2 5.89  1.6 .090
7.8 15.1  8.0 .311
28.0 59.9  22.5 .938
.5) 35 (44.3) .546
20.4 127.9  13.2 .007
25.1 35.4  23.6 .024
8.8 73.1  8.8 .035
18.7 21.2  18.6 .012
ow velocity; E=, early diastolic velocity of mitral annulus; E/A, early-to-late
omerular filtration rate; IVRT, isovolumetric relaxation time measured with
he end diastole; IVSs, intraventricular septum thickness at the end systole;ers a
3 mo
60 
62 
90 
90 
.5 
.6 
80 
01 
11 
97 
.9 
.1 
4 (42
.1 
.8 
.7 
.4 
ral infl
ted glVMI in women (r  0.178; P  .253 and r  0.129;
f
t
t
m
m
r
p
i
d
p
n
f
d
f
s
a
D
a
m
w
l
e
r
i
P
n
.
b
b
n
b
l
i
i
h
i
h
r
p
g
b
a
m
a
u
i
b
C
l
A
C
A
JOURNAL OF VASCULAR SURGERY
March 2011696 Rzeznik et alP .406, respectively) and in men (r0.044; P .803
and r  0.092; P  .604, respectively).
DISCUSSION
There are little data available, and those that exist are
rather conflicting about the interrelations between
LVM, LV diastolic function, SBP, DBP, and outcomes
following RAS.14,15,20
In the present study, we have demonstrated that LVM
and LVMI reduction were observed in 70% of patients with
confirmed hypertension after successful renal artery revas-
cularization. These results are in line with findings of Sy-
monides et al, who observed that successful renal revascu-
larization was followed by regression of left ventricle
hypertrophy, which was evident within 6 months post-
intervention.14However, as opposed to our study, in which
we could observe a steady reduction in LVM and LVMI
over a one-year period, in the study of Symonides et al,
LVM and LVMI did not change significantly between 6
and 12 months of follow-up.14 In both studies, the degree
of LVM and LVMI reduction correlated positively with a
higher baseline LVM, LVMI, and IVS thickness. Also,
Zeller et al reported a significant LVMI reduction that
continued up to 1 year following RAS procedure.15
The LVM reduction following RAS is a matter of
debate. In view of the beneficial effects of ACE and ARB
inhibitors on LV function and slowing down atherosclero-
sis progression, all patients with unilateral renal artery ste-
nosis were administrated ACE or ARB inhibitors long
before RAS, and then these drug regimens were maintained
postprocedurally. Thus, we believe that LVM regression
was independent of ACE or ARB inhibitors action.
In the present study, LVM reduction was indepen-
dently associated with a baseline ejection fraction and high
baseline LVM. To our knowledge, the relationship be-
tween LVM change and LV ejection fraction was not
analyzed by the others.
The relationship between LVM and LVMI reduction
and change in blood pressure values is a matter of debate.
Neither in our study nor in the study conducted by Zeller et
al, there was no correlation between the degree of LVM
and LVMI change and blood pressure values. Concur-
rently, some authors observed that LVMI reduction was
proportional to the blood pressure reduction.15-26 Yoshi-
tomi et al observed that changes in mean blood pressure
and LVMI were significantly correlated (r 0.77; P .01)
in patients with unilateral renovascular hypertension.26 In
the Symonides et al study, there was a positive correlation
between the decrease in SBP and LVMI reduction (r 
0.38; P .05), but there was no correlation between DBP
and LVMI in patients with atherosclerotic renal artery
stenosis.14 However, no correlations between SBP, DBP,
and LVMI were noted for patients with fibromuscular
dysplasia.14
In the present study, we have observed that a baseline
LVM prior to RAS was an independent risk factor of
cardiovascular events. Zeller et al found that survival after
RAS depends on baseline serum creatinine and left ventricle Dunction.27 Corriere et al observed in a group of 20 patients
reated with RAS that regression of left ventricular hyper-
rophy has been associated with reduced CV mortality and
orbidity.20
Some disappointment is related to lack of the improve-
ent in any of diastolic function parameters (E wave, E/E=
atio, IVRT) and no correlation with blood pressure im-
rovement following RAS procedure. Similarly to our find-
ngs, the study of Corriere et al found that a baseline
iastolic function was abnormal in the majority of patients
rior to RAS.20 However, neither in Corriere et al’s study,
or in the present one, no significant change in diastolic
unction parameters on echocardiography was observed
uring the follow-up.20 Improvement in diastolic function
ollowing RAS could have been expected given the ob-
erved decreases in LVM, LVMI, SBP, and DBP, but the
bsence of significant change is difficult to interpret.
The significant clinical improvement in mean SBP and
BP values was seen in 37.9% of patients, and we observed
significant reduction in the number of antihypertensive
edications. The mean SBP reduction and DBP reduction
ere 6.6 mm Hg and 2 mm Hg, respectively, which was
ower as compared with the studies of Beck et al and Rastan
t al.12,21 Rastan et al observed a significant mean BP
eduction of 9 mm Hg,21 whereas Beck et al found signif-
cant improvements in SBP (161 mm Hg vs 144 mm Hg;
 .001), DBP (80 mmHg vs 73 mmHg; P .001), and
umber of antihypertensive medications (3.1 vs 2.8; P 
034) at last follow-up visit.12
A number of the independent factors associated with
lood pressure improvement were postulated, including
ilateral renal stenosis, high baseline mean blood pressure,
ormal renal parenchymal thickness, and a baseline level of
rain natriuretic peptide,6,14,15,21,22,27,28-30 while a base-
ine eGFR 40 mL/min/1.73 m2 was identified as an
ndependent predictor of failure to achieve blood pressure
mprovement.12 In the study by Leesar et al, translesional
yperemic systolic gradient in renal artery equal or exceed-
ng 21 mm Hg provided the highest accuracy in predicting
ypertension improvement after RAS, suggesting significant
enal artery stenosis.22 We have identified the following inde-
endent factors associated with hypertension improvement:
rade of renal artery stenosis, bilateral RAS procedure, and
aseline DBP value. These data strongly suggest that only
dequate referral to RAS procedure can produce improve-
ent in blood pressure values.
In conclusion, RAS is associated with a significant LVM
nd LVMI reduction observed during 12-month follow-
p. There were no significant correlations between change
n LVMor LVMI and reduction of blood pressure values. A
aseline LVMwas identified as an independent predictor of
V events following RAS procedure. No benefit in terms of
eft ventricle diastolic function was seen.
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